Glioblastoma
Conditions
Interventions
Observation group:None
Sponsors
Chongqing Huatan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (1) patients diagnosed with the first recurrence of glioblastoma via clinicoradiological confirmation following the Stupp standard treatment protocol [1]; (2) patients received bevacizumab (Avastin; Roche) at 10 mg/kg, either alone or alongside other drugs such as temozolomide, irinotecan, oxaliplatin, or 5-fluorouracil, with differing dosage schedules; (3) availability of baseline MRI examinations including T2WI, T2-FLAIR, CE-T1WI, and conventional DSC perfusion prior to antiangiogenic therapy; (4) between the initiation of antiangiogenic therapy and tumor progression, at least three consecutive MRI scans (using the same protocol as baseline) were performed, with each scan separated by a minimum interval of one month; (5) serum VEGF was measured once before antiangiogenic therapy and three consecutive times after the initiation of treatment, with at least a two-week interval between each measurement.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: (1) patients with less than 3 follow-up MRI examinations after the initiation of antiangiogenic therapy; (2) patients who underwent additional therapeutic interventions including reoperation, re-irradiation, or other immunotherapies; (3) patients who exhibited tumor progression during the first three consecutive MRI scans after the initiation of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cerebral Blood Volume (CBV);Time to progression, TTP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression mode; | — |
Countries
China
Contacts
Public ContactHuiyu Ruan
Chongqing Huatan Hospital
Outcome results
None listed